Enter
EN
  • TW
  • EN
  • About UBIP
    • Company Overview
    • Milestone
      • 2024
        • Nov 8
        • Oct 18
        • Oct 12
        • Sep 20
        • May 09
        • May 02
      • 2023
        • Dec 15
        • Dec 05
        • Oct 31
        • Oct 25
        • Spe 14
        • Spe 4
        • July 24
        • March 10
        • February 7
      • 2022
        • Nov 28
        • Nov 17
        • Jan 20
      • 2021
        • Nov 22
        • Oct 5
        • Jun 23
        • Jun 11
      • 2020
        • Sep 22
        • May 28
        • Apr 28
        • Apr 14
        • Feb 17
      • 2019
        • Oct 24
        • Sep 26
        • Aug 13
        • Jun 10
        • Mar 13
        • Mar 6
        • Mar 4
        • Jan 18
        • Jan 16
      • 2018
        • Dec 4
        • Oct 3
        • May 17
        • May 11
        • Mar 3
      • 2017
        • Dec 7
      • 2016
        • Dec 14
        • Nov 29
        • Oct 27
        • Aug 15
        • Jul 25
        • Jul 11
        • Feb 18
        • Jan 22
        • Jan 21
      • 2015
        • Dec 30
        • Dec 25
        • Dec 22
        • Nov 17
        • Oct 28
        • Jul 28
        • Jun 23
        • May 28
        • May 8
        • Apr 30
        • Jan 27
        • Jan 23
      • 2014
        • Jul 31
    • Management Team
      • Chairman of the Board & CEO
      • Vice General Manager
  • Technology Platform
    • Innovative Protein Pharmaceutical Technology Platform
    • Specialty Injectable Development Platform
    • Multicomponent Tablet Formulation Technology Platform
    • Long-Acting Small Molecule Drug Technology Platform
  • RD & Products
    • Pipeline
      • Protein Drugs
      • Small Molecule Pharmaceuticals
      • Generic Drugs
    • own-products
    • Our Patents
      • sFc (single chain Fc) platform
      • Recombinant protein
  • Quality
  • CMO/CDMO Services
    • Tailored Solutions
    • Facility & Capacity
      • Premier Labs
        • Protein Drug ◆ Advanced Technology Lab
        • Generic Small Molecule Drugs ◆ Advanced Technology Lab
      • World-Class Compliant Production Line
      • Pharmaceutical Regulatory Compliance Solutions
  • News
    • Press Release
    • Media Coverage
  • Contact us

Search

TW EN
About UBIP
  • Company Overview
  • Milestone
    • 2024
      • Nov 8
      • Oct 18
      • Oct 12
      • Sep 20
      • May 09
      • May 02
    • 2023
      • Dec 15
      • Dec 05
      • Oct 31
      • Oct 25
      • Spe 14
      • Spe 4
      • July 24
      • March 10
      • February 7
    • 2022
      • Nov 28
      • Nov 17
      • Jan 20
    • 2021
      • Nov 22
      • Oct 5
      • Jun 23
      • Jun 11
    • 2020
      • Sep 22
      • May 28
      • Apr 28
      • Apr 14
      • Feb 17
    • 2019
      • Oct 24
      • Sep 26
      • Aug 13
      • Jun 10
      • Mar 13
      • Mar 6
      • Mar 4
      • Jan 18
      • Jan 16
    • 2018
      • Dec 4
      • Oct 3
      • May 17
      • May 11
      • Mar 3
    • 2017
      • Dec 7
    • 2016
      • Dec 14
      • Nov 29
      • Oct 27
      • Aug 15
      • Jul 25
      • Jul 11
      • Feb 18
      • Jan 22
      • Jan 21
    • 2015
      • Dec 30
      • Dec 25
      • Dec 22
      • Nov 17
      • Oct 28
      • Jul 28
      • Jun 23
      • May 28
      • May 8
      • Apr 30
      • Jan 27
      • Jan 23
    • 2014
      • Jul 31
  • Management Team
    • Chairman of the Board & CEO
    • Vice General Manager
  • Home
  • About UBIP
  • Milestone
  • 2015
  • Oct 28

Oct 28


UBI Pharma Inc.
  • TEL +886-3-5977676
  • FAX +886-3-5981173
  • Address No.45, Guangfu N. Rd., Hukou Township, Hsinchu County 303036, Taiwan (R.O.C.)
  • Adverse Reaction Contact
  • 24 hour phone +886-800-035-511
  • email pharmacovigilance@ubi-pharma.com
Privacy Policy
© 2026 UBI Pharma Inc. All rights reserved. Designed By  Winho